Enliven Therapeutics to Present at Two Upcoming Investor Conferences

Rhea-AI Summary

Enliven Therapeutics (Nasdaq: ELVN), a clinical-stage precision oncology company, has announced its participation in two investor conferences in June 2024. The company will present at the Jefferies Global Healthcare Conference on June 5 at 8:30 a.m. ET and the Goldman Sachs Annual Global Healthcare Conference on June 10 at 3:20 p.m. ET. Both events will feature fireside chats with Enliven's management. The sessions will be webcast live and available on the company's investor relations website, with archives accessible for 30 days post-event.

Positive

• Announcement of participation in high-profile investor conferences, enhancing visibility.
• Webcast availability increases access for investors, potentially broadening the investor base.
• Potential to attract new investments through detailed presentations and Q&A sessions.

Negative

• No new financial or clinical data disclosed, providing immediate impact on stock performance.
• Investor conference presentations might not significantly influence long-term stock value.
• Absence of concrete updates or developments regarding ongoing clinical trials or business expansions.

BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June: 

Jefferies Global Healthcare Conference
Format: Fireside Chat
Date: Wednesday, June 5
Time: 8:30 a.m. ET

Goldman Sachs Annual Global Healthcare Conference
Format: Fireside Chat
Date: Monday, June 10
Time: 3:20 p.m. ET

Both fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at https://ir.enliventherapeutics.com/. Each webcast will be archived for a period of 30 days following the conclusion of the live event.

About Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help people with cancer not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven’s discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.

Contact
Investors
ir@enliventherapeutics.com

Media
media@enliventherapeutics.com

FAQ

When will Enliven Therapeutics present at the Jefferies Global Healthcare Conference?

Enliven Therapeutics will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 8:30 a.m. ET.

What is the date and time for Enliven Therapeutics' presentation at the Goldman Sachs Annual Global Healthcare Conference?

The presentation at the Goldman Sachs Annual Global Healthcare Conference will take place on June 10, 2024, at 3:20 p.m. ET.

Where can I access the webcasts for Enliven Therapeutics' presentations?

The webcasts will be available on Enliven Therapeutics' investor relations website and archived for 30 days following the events.

What type of presentations will Enliven Therapeutics conduct at the conferences?

Enliven Therapeutics will conduct fireside chats at both conferences.

What is the stock symbol for Enliven Therapeutics?

The stock symbol for Enliven Therapeutics is ELVN.